Like Riluzole, the only approved ALS treatment to date, the vast majority of drugs currently considered for clinical trials are based on animal models with SOD1-mutant background (85% in a recent survey [123]). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.